niacinamide has been researched along with lovastatin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Cefali, E; Menon, R; Tolbert, D | 1 |
| Bil, J; Golab, J; Jakobisiak, M; Nowis, D; Zapala, L | 1 |
| Cirone, M; D'Orazi, G; Gilardini Montani, MS; Gonnella, R; Pompili, C; Romeo, MA; Santarelli, R | 1 |
1 trial(s) available for niacinamide and lovastatin
| Article | Year |
|---|---|
The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Female; Flushing; Humans; Lovastatin; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Niacin; Niacinamide; Nicotinic Acids; Pyridones; Tablets; Time Factors; Vitamin B Complex | 2007 |
4 other study(ies) available for niacinamide and lovastatin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mice; Myocytes, Cardiac; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Prenylation; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib | 2010 |
Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Humans; Lovastatin; Lymphoma, Primary Effusion; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Phosphorylation; STAT3 Transcription Factor; Tumor Suppressor Protein p53; Tyrosine | 2021 |